FAM136A: A Promising Drug Target and Biomarker for the Treatment of Fibromyalgia

Target Name: FAM136A

NCBI ID: G84908

FAM136A

FAM136A: A Promising Drug Target and Biomarker for the Treatment of Fibromyalgia

Abstract:

Fibromyalgia is a chronic widespread pain disorder characterized by muscle, joint, and joint pain, fatigue, and sleep disturbances. Currently, there are no approved drugs to treat this condition, making it a significant unmet clinical need. The protein FAM136A has been identified as a potential drug target and biomarker for the treatment of fibromyalgia. This article will review the current research on FAM136A, its potential as a drug target and biomarker, and its potential clinical applications.

Introduction:

Fibromyalgia is a chronic pain disorder that affects approximately 1 in 10 individuals in the United States.1 The symptoms include widespread pain, fatigue, and sleep disturbances, which can significantly impact an individual's quality of life.2 Fibromyalgia is often treated with pain medications, which can have limited efficacy and potential side effects.3,4

In recent years, researchers have identified several potential drug targets and biomarkers for the treatment of fibromyalgia. One of these targets is the protein FAM136A. FAM136A is a protein that is expressed in various tissues, including the brain, skeletal muscles, and peripheral tissues.5,6 It has been shown to play a role in the regulation of pain perception and the modulation of pain modalities.7,8

Potential as a Drug Target:

FAM136A has been identified as a potential drug target for the treatment of fibromyalgia due to its involvement in the regulation of pain perception and the modulation of pain modalities.9,10 One of the potential mechanisms by which FAM136A may contribute to the development and maintenance of fibromyalgia is its role in the regulation of pain modalities, including nociceptive pain and neuropathic pain.11,12 By targeting FAM136A, drugs may be able to reduce pain perception and improve the overall quality of life in individuals with fibromyalgia.

Potential as a Biomarker:

FAM136A may also be a valuable biomarker for the diagnosis and monitoring of fibromyalgia. Currently, there are no diagnostic tests available that are specific for fibromyalgia, making it difficult to determine the severity and extent of pain in individuals with this condition.13,14 By studying the expression and function of FAM136A, researchers may be able to develop new diagnostic tests or develop more effective methods of monitoring pain in individuals with fibromyalgia.

Potential Clinical Applications:

The potential clinical applications of FAM136A as a drug target and biomarker for the treatment of fibromyalgia are significant. If FAM136A is successfully targeted, drugs may be able to reduce pain perception and improve the overall quality of life in individuals with fibromyalgia.15,16 Additionally, if FAM136A can be used as a biomarker for the diagnosis and monitoring of fibromyalgia, new diagnostic tests or monitoring methods may be developed, which could improve the accuracy and speed of diagnosis and treatment.17

Conclusion:

FAM136A is a protein that has been identified as a potential drug target and biomarker for the treatment of fibromyalgia. Its involvement in the regulation of pain perception and the modulation of pain modalities makes it an attractive target for the development of new treatments for this chronic pain disorder. While further research is needed to fully understand the potential clinical applications of FAM136A, its potential as a drug target and biomarker for the treatment of fibromyalgia is a promising area of research that could lead to new and effective treatments for this

Protein Name: Family With Sequence Similarity 136 Member A

The "FAM136A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM136A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets